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Introduction. Chlamydia trachomatis (Ct) is the most common bac-
terial cause of sexually transmitted infections (STI) and is associated 
with severe long-term sequelae in female populations.
In Italy Ct infections are not submitted to a screening programme, 
and its epidemiological profile is understudied. Even scarcer infor-
mation is available about the genetic diversity on ompA gene, whose 
sequence defines 18 different genovars. This study aims at evaluating 
the prevalence of Ct infection in young sexually active asymptomatic 
women aged 18-25, and characterizing the molecular epidemiology 
of the different circulating genovars in this population.
Methods. Cervical samples collected from 909 sexually-active-
young women (mean age 21.5 years) were analyzed through 
molecular assay for the detection of Ct infection. Phylogenetic 
analysis on the ompA gene was performed on Ct positive samples 
to identify the circulating genovars.
Results. The overall prevalence of Ct-infection was 4.4% (95%CI: 
3.2-5.9%): 5.3% among women aged 18-21 years and 3.5% 
among those aged 22-25 years. Phylogenetic analysis has identi-
fied 5 different genovars: D, E, F, G, and H. The most common 
genovar was the E (46%), followed by genovar F and G (18.9% 
each), D (13.5%), and H (2.7%).
Conclusions. This study underlines the high prevalence of asymp-
tomatic Ct-infections among young women. Overall, about half 
of the asymptomatic infections is sustained by genovar E. The 
introduction in Italy of a systematic screening program should be 
considered to allow a better understanding of Ct spreading and 
providing women with an opportunity for early treatment to pro-
tect their sexual and reproductive health.
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Introduction
Chlamydia trachomatis (Ct) is an obligate intracellular 
Gram-negative bacterium that is the most commonly 
reported microorganism responsible for sexually trans-
mitted infections (STI) in Europe and is the cause of 
considerable acute morbidity and long term reproduc-
tive health problems, particularly in young people [1, 2]. 
Many infections are asymptomatic and result in delayed 
diagnosis and uninterrupted transmission. This is of par-
ticular clinical relevance as untreated infections can as-
cend in the female genital tract and cause Pelvic Inflam-
matory Disease (PID), which includes any combination 
of endometritis, salpingitis, tubo-ovarian abscess and 
pelvic peritonitis. PID can also result in ectopic preg-
nancy, infertility and chronic pelvic pain [2-4]. 
The presence of few or no specific symptoms that, if 
untreated, could lead to an increase in female reproduc-
tive tract morbidity and the existence of an inexpensive 
treatment against all these infections make chlamydia 
screening widely recommended to all sexually active 
women aged 25 or less [5-7]. In fact, Ct is under epide-
miological surveillance in several European regions and 
the reported prevalence in young sexually active women 
ranges from 5% to 10%. Infection rates are the highest 
in females below 20 years of age and decrease with in-
creasing age [8, 9]; in 2007, the incidence of chlamydial 
infection was 4.5-fold higher in the age group 15 to 24 
years than in the age group 25-44 years [9].
In Europe the incidence of genital Ct infections seems to 
have increased dramatically over the last 20 years. How-
ever, this is most likely the result of more extended testing 
rather than a true rise in the incidence. Targeted screen-
ing, opportunistic testing for asymptomatic infections, 
contact tracing and mandatory notification help to explain 
the high notification rates in the UK and the Scandinavian 
countries compared with other European states [10].
In Italy, a reporting system for Chlamydia infections is not 
in place and an organised screening in specific asymptom-
atic population groups is not available. Surveillance data 
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are collected centrally by the Istituto Superiore di Sanità 
(ISS) by a sentinel network system consisting of 13 mi-
crobiology laboratories located throughout the Country. 
The last report, regarding data until 2012, described an 
overall prevalence of 2.4% in women aged between 15 
and 45 years, with a significantly increased prevalence 
in lower age groups [11]. Moreover, a recent study iden-
tified 5.2% of Ct endocervical infection prevalence in a 
large population of sexually active women aged 15-55 
years attending an outpatient service of cervico-vaginal 
pathology unit in Rome over a 10-year period [12]. Not-
withstanding the existence of these studies, knowledge 
on the prevalence and molecular epidemiology of Chla-
mydial genital tract infections, particular in young as-
ymptomatic women, remains modest. 
Molecular epidemiology studies are currently based on 
the analysis of differences in the Ct major outer mem-
brane protein (MOMP), whose coding gene (ompA) 
contains four spaced variable domains. Genetic variabil-
ity on ompA gene reflects the existence of 18 genovars, 
classified according to their pathogenic potential  [13]. 
Genovars A, B, Ba, and C have been commonly as-
sociated with trachoma, D-K, Da, Ia, and Ja with uro-
genital infections, and L1-L3 with lymphogranuloma 
venereum [13]. In addition, on the basis of amino acid 
similarities, these genovars have been grouped into the 
following groups or classes: group B (B, Ba, D, Da, E, 
L1, and L2), group C (A, C, H, I, Ia, J, Ja, K, and L3), 
and the intermediate group (F and G) [14]. These type 
of studies are useful to obtain new information about Ct 
genovars distribution, which can be further on translated 
into improved strategies for Ct infection management, 
for the traceability of sexual contacts, and in developing 
strategies for vaccine design [15, 16].
To improve our knowledge about Ct epidemiology and 
to expand the available Italian data, we evaluate here the 
prevalence of Ct infections and the molecular epidemi-
ology of circulating genovars in young asymptomatic 
sexually active women aged 18-25 in Milan, Italy, over a 
period of 6 years (2008-2013).
Materials and methods
Study population
This was a cross-sectional study, performed on female 
subjects who spontaneously visited gynecological cen-
ters of the Local Health Units (LHUs) of Milan for 
medical consultations for contraception. No evidence 
of clinical symptoms related to Ct infection were de-
scribed by the physician. Cervical cytological samples 
were collected for routine test among women aged 18 
to 25 years, from September 2008 to June 2013. Writ-
ten informed consent was obtained from young women 
so as to store their samples for further anonymous re-
search testing. Due to its design, ethical approval was 
not required for this study, in compliance with the inter-
national policy [17] and with the current Italian legisla-
tion [18, 19]. The database was anonymised before the 
analysis.
Samples collection
Cervical cytological samples were collected using 
a brush (Cytobrush Plus Medscand® Medical AB, 
Sweden), immersed and rinsed in a vial filled with 20 ml 
of PreservCyt® Solution (PreservCyt) and stored at room 
temperature (RT) until processing. A total of 10 ml of 
each PreservCyt® Solution containing cervical cells was 
centrifuged at 3800xg for 15 min at RT. After centrifu-
gation the pellet was re-suspended in 1 ml of Phosphate 
Buffered Saline (PBS), transferred in a new 1.5 ml col-
lection test tube, and stored at -20°C until nucleic acids 
extraction.
DNA extraction and amplification
DNA was extracted with the EasyMAG kit (NucliSENS® 
easyMAG®, bioMérieux, France) from 500 µl of the re-
suspended pellet with a final elution volume of 100 µl. 
The concentration and purity of the extracted DNA was 
evaluated through a spectrophotometer (NanoDrop ND-
2000/200C, Euroclone®, Thermo Scientific, Wilming-
ton, DE, USA). After DNA extraction molecular tests 
were promptly performed to limit the storage to a maxi-
mum of a week. DNA integrity was assessed by the am-
plification of a 268 bp fragment of the ubiquitous beta-
globin gene using the primer pair GH20 and PCO4 [20]. 
A nested PCR targeting a Ct cryptic plasmid was per-
formed to screen each extracted sample. The primers 
used for the nested PCR were previously described by 
Jalal et al. [21] and amplify a fragment of 150 nt. Ampli-
fications were performed on 50 ng of extracted DNA in 
a 50 µlreaction mix containing 5x PCR Buffer, 200 µM 
dNTPs, 25 pmol of each primer, and 1 U Taq (GoTaq® 
DNA Polymerase 5U/µl Promega, Madison WI). Each 
run was accompanied by positive and negative control 
samples. The cycling conditions were as follow: 94°C 
for 5 min, followed by 30 cycles of amplification during 
the first step and 25 cycles during the nested step con-
sisting of 94°C for 30 sec, 50°C for 30 sec, 72 °C for 30 
sec, and a final 72°C for 7 minutes extension. The final 
amplification products were visualized using electro-
phoresis analysis on a 2% agarose gel containing ethid-
ium bromide (0.5 mg/L) and compared with a standard 
(DNA Molecular Weight, Marker 100, SigmaAldrich, 
St. Louis, MO, USA).
All Ct-DNA positive samples were used to amplify a 
395 bp fragment of the Ct ompA gene with previously 
described primer sets  [21]. Amplifications were per-
formed on 50 ng of extracted DNA in a 50 µl reaction 
mix containing 5x PCR Buffer, 200 µM dNTPs, 25 pmol 
of each primer, and 1 U Taq (GoTaq® DNA Polymerase 
5U/µl Promega, Madison WI). The cycling conditions 
were: 94°C for 5 min, followed by 30 cycles during the 
first amplification round or 25 cycles during the second 
round of 94°C for 30 sec, 50°C for 30 sec, 72 °C for 30 
sec, and a final 72°C step for 7 minutes. 
Following the PCR of the ompA gene fragments, am-
plification products were purified using NucleoSpin® 
Extract II (Macherey-Nagel GmbH, Germany) and nu-
cleotide sequences were obtained from automated DNA 
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sequencing on the ABI PRISM 3100 genetic analyzer 
(Applied Biosystem, CA, USA). 
Phylogenetic analysis
Molecular characterization was performed by analysis 
of 395 bp amplicons of the ompA Ct gene (nucleotides 
223-636 of Ct genovar A sequence, NC007429). All 
specimens presenting ompA variant sequences were con-
firmed by resequencing newly extracted DNA.
All sequences obtained in this study were deposited into 
NCBI GeneBank Database [27], under accession numbers: 
KX449367-KX449406. The reference genovars used for 
the construction of phylogenetic trees were obtained from 
the NCBI GenBank Database (genovar A: NC007429, 
M58938; genovar B: AF063194, U80075, M33636; geno-
var C: M17343; genovar D: NC000117, X62920, X62918, 
X62919; genovar E: X52557; genovar F: X52080; genovar 
G: AF063199; genovar H: X16007; genovar I: AF063200; 
genovar J: AF063202; genovar K: AF063204; genovar L1: 
M36533; genovar L2: M14738; genovar L3: X55700). 
Sequences were aligned using ClustalX 2.1 multiple align-
er [22] and then used for phylogenetic inference. A model 
selection was performed to identify the best model for dis-
tance estimation. The evolutionary history was inferred 
using the maximum-likelihood method [23] based on the 
Tamura 3 parameter model [24], identified as the best fit-
ting model after the model test analysis, using MEGA 
6.06 [25]. A discrete Gamma distribution was used to mod-
el evolutionary rate differences among sites (G = 0.8952) 
and phylogenetic trees were constructed with MEGA 6.06. 
A bootstrap test [26] with 1,000 replicates was performed 
to test the robustness of the analyses.
Statistical analysis
Data were expressed as mean (range) and percentages 
(95% confidence intervals, 95% CI) where appropriate. 
Comparisons between groups were performed using the 
chi-square test or Fisher’s exact test. A p-value < 0.05 
was considered statistically significant (two-tailed test). 
All statistical analyses were performed using OpenEPI 
software, version 2.3.1 [28].
Results
Prevalence of Ct infection
A total of 909 samples collected from the same number 
of sexually active young women (mean age 21.5 years, 
range 18-25 years) were available for this study. All 
women were asymptomatic for Ct infection. 
The beta-globin gene was successfully amplified from 
all 909 cervical samples collected, confirming the suit-
ability of the extraction method for these biological sam-
ples (extracted DNA: mean 20.1 ng/µl, range [3.3-45.7 
ng/µl]). 
The overall prevalence of Ct infections was 4.4% (95% 
CI, 3.2-5.9%). The prevalence of Ct infection was the 
highest among 20-21 year-old women with a value of 
5.5% (95% CI, 3.0-9.3%) and decreased to 3.5% (95% 
CI, 1.5-6.7%) and 3.6% (95% CI, 1.6-6.9%) in age 
groups 22-23 and 24-25 years (Tab. I). Differences be-
tween infection rates in the different age groups and 
during the different years of the study period were not 
significant.
Molecular characterization
OmpA amplification was successful for 37 out of 40 
positive samples (92.5%). Phylogenetic analysis of the 
ompA partial nucleotide sequences demonstrated 5 dif-
ferent genovars: D, E, F, G, and H (Fig. 1). In particular, 
2 genovars (D and E) fell into subgroup B, 2 (F, and G) 
fell into the intermediate subgroup, and one, genovar H, 
fell into subgroup C. All circulating genovars are nor-
mally associated with infection of the urogenital tract. 
The most common genovar in our population was 
E (46%, 17/37), followed by genovars F and G (both 
18.9%, 7/37), D (13.5%, 5/37), and H (2.7%, 1/37). No 
genovar distribution pattern was observed among the 
various age groups (Fig. 2), and during the different 
years of the study period (Fig. 3).
Discussion
Chlamydia trachomatis is the most common bacterium 
associated with STIs and genovars D-K cause geni-
tal tract infections in women (cervicitis and urethritis) 
and men (urethritis). These can also be responsible for 
sexually transmitted rectal and pharyngeal infections, 
be transmitted during labor, cause pneumonia and eye 
infections in infants, and be spread by close contact to 
cause eye infections in adults. Several data suggest that, 
even though young people aged 15-24 years represent 
only 25% of the sexually experienced population, they 
acquire nearly half of all new STIs  [29]. Rates of re-
ported chlamydial infection among persons aged 15-19 
years and 20-24 years continue to increase. Overall, dur-
ing 2009-2010, rates increased up to 2.8% and 7.5% in 
the age groups 15-19 and 20-24 years, respectively [30]. 
Compared with older women, sexually active adoles-









18-19 220 (24.2%) 11 (27.5%) 5.0% 2.5-8.8
20-21 235 (25.9%) 13 (32.5%) 5.5% 3.0-9.3
22-23 230 (25.3%) 8 (20.0%) 3.5% 1.5-6.7
24-25 224 (24.6%) 8 (20.0%) 3.6% 1.6-6.9
Total 909 (100.0%) 40 (100.0%) 4.4% 3.2-5.9
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cents aged 15-19 years and young adults aged 20-24 
years are at higher risk of acquiring STIs for a com-
bination of behavioural, biological, and cultural rea-
sons [31]. 
This study focused on asymptomatic sexually active 
young women and describes the molecular epidemi-
ology of Ct in Milan, Italy, over a period of 6 years. 
The prevalence of the infection was 4.4%, in line with 
what reported by other Italian studies [11, 12, 32, 33]. 
The most common genovars found in our populations 
were E (46%), F and G (both to 18.9%). Other recent 
studies described E (50-33%) and F (25-14%) as the 
most common genovars in symptomatic female popu-
lations [34-36]. A previous study, conducted in Italy in 
symptomatic and asymptomatic populations attending 
a Sexually Transmitted Disease (STD) outpatient clin-
ic, described gerovar E as the most prevalent in female 
(37.2%), followed by genovar G (32.6%), and genovar F 
Fig. 1. Phylogenetic analysis of C. trachomatis partial ompA gene sequences (coded between nt 223-636 of C. trachomatis genovar A, 
accession number NC007429) obtained during this study and compared to reference sequences. The outcome of the bootstrap analysis 
is shown next to the nodes, and branch lengths are proportional to genetic distances as indicated by the scale bar. Genovars as well as 
subgroups are indicated on the right.
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Fig. 3. Overall Ct infection prevalence (line) with 95% CI (vertical lines) and genovar distribution (bars) during the different years of the 
study. The vertical axis on the left refers to the genovar distribution, while the one on the right refers to prevalence values. NT: not typed. 
Fig. 2. Genovar distribution among the studied age groups.
and J (both to 7%), regardless of presence or absence of 
related symptoms [37]. 
It has been demonstrated that genovars E and F have a 
biological advantage over the other genovars thanks to 
both their ability to escape the host immune response 
and the presence of specific virulence factors, which 
can facilitate the transmission and infectious process-
es  [38, 39]. It is possible that genovars E and F are 
less immunogenic than other genovars and, therefore, 
remain the most prevalent strain in all populations, 
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regardless of the presence or absence of clinical signs.
Although we could not detect any relationship between 
infection, related genovar, and absence of symptoms, the 
present study contributed to increase the current knowl-
edge on genotype distribution of Ct in asymptomatic 
young women in northern Italy. 
Conclusions
Our data indicate that Ct infections occur frequently in 
young sexually active women and that several different 
genovars are widely spread in Italy. Larger national and 
longitudinal studies are definitively required to better 
understand the spread of Ct infection and its impact on 
the young Italian population.
These results underscore the need to establish primary 
and secondary preventive measures and to allocate more 
resources for an adequate prevention of Ct infections. 
The introduction of an opportunistic screening program 
for Ct in Italy should be evaluated in order to achieve 
early treatment of infected subjects and reduce associ-
ated clinical manifestations. Finally, it seems essential 
to develop educational programs and information cam-
paigns, particularly addressed to young people, about 
acquisition, risk factors and treatment of STIs with a 
particular focus on C. trachomatis infection.
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